非侵入性产前检测市场－全球产业规模、份额、趋势、机会及预测（依产品类型、检测类型、方法、应用、最终用户、地区及竞争格局划分，2021-2031年）

全球非侵入性产前检测 (NIPT) 市场预计将从 2025 年的 52.5 亿美元成长到 2031 年的 82.3 亿美元，复合年增长率达到 7.78%。

非侵入性产前检测 (NIPT) 是一种先进的筛检技术，可透过检测母体血液中存在的游离胎儿 DNA 来识别染色体非整倍体，例如 21 三体综合征、18 三体综合征和 13 三体综合征。推动该市场成长的主要因素是全球孕妇平均年龄的成长，以及人们对安全、非侵入性的替代传统侵入性诊断方法（例如羊膜穿刺术）的明显偏好。此外，检测能力的不断提升，使其能够涵盖更广泛的疾病，也促进了其应用。例如，诊断和实验室医学协会 (ADLM) 在 2025 年报告称，研究证实了这些筛检测试的广泛效用，例如在 2.1% 的妊娠中检测到巨细胞病毒DNA，凸显了其在全面评估胎儿健康方面的潜力。

儘管有这些有利因素，但检测成本高昂和报销制度不统一仍然是市场推广的重大障碍。这些经济障碍限制了公众，特别是开发中国家和低收入群体获得检测的机会，并阻碍了非侵入性产前检测（NIPT）成为广泛产前保健的标准检测项目。因此，这些经济障碍阻碍了全球市场达到完全饱和。

市场驱动因素

对于诊断服务提供者而言，在非侵入性产前检测 (NIPT) 领域拓展全球业务和提升能力，主要市场参与者之间的策略联盟与合作至关重要。透过收购和与区域实验室建立合作关係，主要企业正在整合市场、强化分销网络，并将专业检测技术纳入其产品组合。这种整合将使他们能够为不同的患者群体提供高效的产前筛检服务，并加速推广全面的女性健康解决方案。例如，LabCorp 在 2025 年 2 月发布的「2024 年第四季及全年财务表现」报告中指出，该公司在 2024 年完成了 10 项交易，巩固了其作为医疗保健系统值得信赖的合作伙伴的地位。这显着增强了该公司在女性健康等高成长领域的实力。

全球平均生育年龄的上升是推动染色体异常筛检需求持续成长的主要因素。随着社会经济因素不断推迟生育年龄，高龄生产带来的染色体异常临床风险增加，使得可靠、非侵入性的胎儿健康评估变得特别重要。美国疾病管制与预防中心 (CDC) 于 2025 年 4 月发布的报告《胎儿出生：2024 年初步数据》强调了这一重要的人口结构变化，预测 2024 年 40-44 岁女性的生育率将比前一年增长 2%。高危险妊娠的增加与产前检测使用率的提高有直接关係。 2025 年 2 月，Myriard Genetics 公司报告称，其产前检测收入比上一年增长了 12%，这反映了推动这些重要筛检检测需求的强劲人口压力。

市场挑战

全球无创产前检测 (NIPT) 市场受到高昂检测费用以及不同地区和保险公司报销政策不一致的严重限制。儘管 NIPT 的准确性已得到认可，但高昂的自付费用对很大一部分人群构成了重大障碍，尤其是在开发中国家以及保险覆盖范围有限或被拒保的中等风险妊娠中。这种经济差距阻碍了 NIPT 成为普遍的医疗标准，使其实际上成为加值服务，而非所有孕妇均可享受的常规医疗程序。

因此，市场渗透率仍然不均衡，成长主要集中在拥有全额保险的人群中。 2025年，德国医学协会指出了这种差异，并透露，由于经济限制，26岁以下孕妇中只有约25%使用NIPT服务，而拥有完善保险的年龄组的使用率则显着更高。这种差异表明，经济因素和支付方政策的不一致直接限制了NIPT市场的规模发展及其在更广泛的产前保健领域达到饱和的能力。

市场趋势

将该检测范围扩大至一般风险妊娠标誌着市场发生了根本性转变，消费群从高风险妊娠人群转向了普通孕妇群体。这项转变的驱动因素包括：所有孕妇（无论年龄大小）筛检的日益标准化，以及在年轻族群中临床疗效不断得到检验。这种广泛的应用导致检测量迅速增长，成为推动产业扩张的新主要动力。例如，Natera公司在其2025年11月发布的「2025年第三季财务业绩」中报告称，该公司已处理了约893,600份检测样本。这比前一年增长了15.2%，主要得益于这些筛检检测在更广泛的患者群体中的广泛应用。

同时，随着综合多基因检测技术的不断发展，该产业也持续演进，其诊断能力已超越了传统的染色体异常检测。製造商们正致力于研发创新检测方法，以识别传统非侵入性检测方法无法检测到的特定单基因疾病和罕见疾病，从而满足早期怀孕阶段对更高诊断准确性的临床需求。这项技术进步使得复杂遗传疾病的筛检成为可能，并提供更深入的基因讯息，从而促进早期疗育。作为这项进步的象征，Natera公司于2025年10月宣布，将把其单基因检测范围扩展至20个基因，显着提升其检测难以发现的纯合突变和严重早发性疾病的能力。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

5. 全球无创产前检测 (NIPT) 市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品类型（耗材、设备）
  • 按测试类型（Materuni 21、Harmony、Panorama、Verifi、NIFTY、其他）
  • 透过方法（超音波、筛检筛检、无细胞DNA母体血浆检测、母体血胎儿细胞检测、其他）
  • 依应用（三体症候群、微缺失症候群等）
  • 依最终用户（诊断检查室、医院等）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美无创产前检测 (NIPT) 市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲无创产前检测 (NIPT) 市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区非侵入性产前检测（NIPT）市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲无创产前检测 (NIPT) 市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲非侵入性产前检测 (NIPT) 市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球无创产前检测（NIPT）市场：SWOT分析

第十四章 波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• YOURGENE HEALTH Plc
• Illumina, Inc.
• Natera, Inc.
• F.Hoffman La Roche Ltd.
• Perkin Elmer Inc.
• Laboratory Corporation of America Holdings
• Eurofins LifeCodex GmbH
• Progenity, Inc.
• Genesis Genetics
• Quest Diagnostics Incorporated

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Non-invasive Prenatal Testing (NIPT) Market is projected to expand from USD 5.25 Billion in 2025 to USD 8.23 Billion by 2031, achieving a CAGR of 7.78%. NIPT serves as an advanced screening technique that examines cell-free fetal DNA found in maternal blood to identify chromosomal aneuploidies, including trisomy 21, 18, and 13. The primary catalysts for this market growth are the rising average maternal age worldwide and a distinct preference for safe, non-invasive alternatives to traditional invasive diagnostic procedures like amniocentesis. Furthermore, the continual enhancement of testing capabilities to cover a wider array of conditions supports increased adoption. For instance, the Association for Diagnostics & Laboratory Medicine reported in 2025 that research confirmed the expanded utility of these screenings by detecting Cytomegalovirus DNA in 2.1% of pregnancies, highlighting the potential for comprehensive fetal health assessments.

Despite these positive drivers, the market encounters a substantial obstacle regarding the high price of testing and variable reimbursement policies. This financial hurdle limits access for the general public, especially within developing nations and lower-income demographics, thereby preventing NIPT from becoming a universally implemented standard in routine prenatal care. Consequently, these economic barriers impede the global market's ability to reach full saturation.

Market Driver

Strategic partnerships and collaborations among leading market players are essential for broadening the global reach and capabilities of diagnostic providers in the NIPT sector. By acquiring regional laboratories and forming alliances, major companies are consolidating the market to strengthen distribution networks and incorporate specialized testing technologies into their portfolios. This consolidation facilitates the efficient delivery of prenatal screening services to diverse patient populations and accelerates the availability of comprehensive women's health solutions. For example, Labcorp announced in its 'Fourth Quarter and Full Year 2024 Results' in February 2025 that it completed 10 transactions throughout 2024 to solidify its position as a trusted partner to health systems, significantly reinforcing its presence in high-growth areas such as women's health.

The rising average maternal age globally serves as a primary catalyst for the sustained demand for chromosomal aneuploidy screening. As delayed childbearing trends continue due to changing socio-economic factors, the increased clinical risk of chromosomal abnormalities in older mothers necessitates reliable, non-invasive fetal health evaluations. According to the CDC's 'Births: Provisional Data for 2024' report released in April 2025, the birth rate for women aged 40-44 rose by 2% in 2024, highlighting this significant demographic shift. This increase in higher-risk pregnancies correlates directly with higher utilization rates of prenatal diagnostics; Myriad Genetics reported in February 2025 that prenatal testing revenue grew 12% year-over-year, reflecting the strong uptake of these essential screenings driven by demographic pressures.

Market Challenge

The Global Non-invasive Prenatal Testing (NIPT) Market is significantly constrained by high testing costs and the absence of consistent reimbursement policies across various regions and insurance providers. Although NIPT is acknowledged for its accuracy, substantial out-of-pocket expenses create a severe barrier to entry for a large segment of the population, particularly in developing economies and among average-risk pregnancies where insurance coverage is frequently denied or limited. This financial disparity prevents the test from becoming a universal standard of care, effectively categorizing it as a premium service rather than a routine medical procedure available to all expectant mothers.

As a result, market penetration remains uneven, with growth heavily concentrated in demographics that benefit from full financial coverage. In 2025, the German Medical Association highlighted this discrepancy, revealing that only approximately 25% of pregnant women under the age of 26 accessed NIPT services due to funding limitations, compared to significantly higher adoption rates in age groups with established reimbursement coverage. This divide illustrates how economic factors and inconsistent payer policies directly restrict the scalable expansion of the NIPT market, limiting its potential to reach saturation in the broader prenatal care sector.

Market Trends

The expansion of testing coverage to include average-risk pregnancies marks a fundamental shift in the market, transitioning the consumer base from exclusively high-risk cases to the broader general population. This evolution differs from demographic drivers as it relies on the normalization of screening as a standard routine for all expectant mothers regardless of age, supported by increasing clinical validation for younger demographics. The uptake in this wider segment is rapidly accelerating test volumes, creating a new primary engine for industry expansion. Evidencing this mass-market adoption, Natera reported in its 'Third Quarter 2025 Financial Results' in November 2025 that the company processed approximately 893,600 tests, a 15.2% increase year-over-year, driven largely by the robust penetration of these screenings into broader patient categories.

Concurrently, the industry is advancing through the development of comprehensive multi-gene panel testing, which extends diagnostic capabilities beyond standard aneuploidy detection. Manufacturers are innovating assays that identify specific single-gene disorders and rare conditions previously undetectable via non-invasive methods, thereby addressing the clinical need for higher diagnostic yield in early pregnancy. This technological evolution enables the screening of complex inherited conditions, providing deeper genetic insights that facilitate earlier interventions. Highlighting this advancement, Natera announced in October 2025 the expansion of its single-gene testing panel to cover 20 genes, significantly enhancing its capability to detect challenging homozygous mutations and severe early-onset disorders.

Key Market Players

• YOURGENE HEALTH Plc
• Illumina, Inc.
• Natera, Inc.
• F.Hoffman La Roche Ltd.
• Perkin Elmer Inc.
• Laboratory Corporation of America Holdings
• Eurofins LifeCodex GmbH
• Progenity, Inc.
• Genesis Genetics
• Quest Diagnostics Incorporated

Report Scope

In this report, the Global Non-invasive Prenatal Testing (NIPT) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-invasive Prenatal Testing (NIPT) Market, By Product Type

• Consumables
• Instruments

Non-invasive Prenatal Testing (NIPT) Market, By Test Type

• Materni 21
• Harmony
• Panaroma
• Verifi
• NIFTY
• Others

Non-invasive Prenatal Testing (NIPT) Market, By Method

• Ultrasound Detection
• Biochemical Screening Testing
• Cell-Free DNA Maternal Plasma Tests
• Fetal Cells in Maternal Blood Tests
• Others

Non-invasive Prenatal Testing (NIPT) Market, By Application

• Trisomy
• Microdeletion Syndrome
• Others

Non-invasive Prenatal Testing (NIPT) Market, By End User

• Diagnostic Laboratories
• Hospitals
• Others

Non-invasive Prenatal Testing (NIPT) Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-invasive Prenatal Testing (NIPT) Market.

Available Customizations:

Global Non-invasive Prenatal Testing (NIPT) Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-invasive Prenatal Testing (NIPT) Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Consumables, Instruments)
  • 5.2.2. By Test Type (Materni 21, Harmony, Panaroma, Verifi, NIFTY, Others)
  • 5.2.3. By Method (Ultrasound Detection, Biochemical Screening Testing, Cell-Free DNA Maternal Plasma Tests, Fetal Cells in Maternal Blood Tests, Others)
  • 5.2.4. By Application (Trisomy, Microdeletion Syndrome, Others)
  • 5.2.5. By End User (Diagnostic Laboratories, Hospitals, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Non-invasive Prenatal Testing (NIPT) Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Test Type
  • 6.2.3. By Method
  • 6.2.4. By Application
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Test Type
      • 6.3.1.2.3. By Method
      • 6.3.1.2.4. By Application
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Test Type
      • 6.3.2.2.3. By Method
      • 6.3.2.2.4. By Application
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Test Type
      • 6.3.3.2.3. By Method
      • 6.3.3.2.4. By Application
      • 6.3.3.2.5. By End User

7. Europe Non-invasive Prenatal Testing (NIPT) Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Test Type
  • 7.2.3. By Method
  • 7.2.4. By Application
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Test Type
      • 7.3.1.2.3. By Method
      • 7.3.1.2.4. By Application
      • 7.3.1.2.5. By End User
  • 7.3.2. France Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Test Type
      • 7.3.2.2.3. By Method
      • 7.3.2.2.4. By Application
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Test Type
      • 7.3.3.2.3. By Method
      • 7.3.3.2.4. By Application
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Test Type
      • 7.3.4.2.3. By Method
      • 7.3.4.2.4. By Application
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Test Type
      • 7.3.5.2.3. By Method
      • 7.3.5.2.4. By Application
      • 7.3.5.2.5. By End User

8. Asia Pacific Non-invasive Prenatal Testing (NIPT) Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Test Type
  • 8.2.3. By Method
  • 8.2.4. By Application
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Test Type
      • 8.3.1.2.3. By Method
      • 8.3.1.2.4. By Application
      • 8.3.1.2.5. By End User
  • 8.3.2. India Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Test Type
      • 8.3.2.2.3. By Method
      • 8.3.2.2.4. By Application
      • 8.3.2.2.5. By End User
  • 8.3.3. Japan Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Test Type
      • 8.3.3.2.3. By Method
      • 8.3.3.2.4. By Application
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Test Type
      • 8.3.4.2.3. By Method
      • 8.3.4.2.4. By Application
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Test Type
      • 8.3.5.2.3. By Method
      • 8.3.5.2.4. By Application
      • 8.3.5.2.5. By End User

9. Middle East & Africa Non-invasive Prenatal Testing (NIPT) Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Test Type
  • 9.2.3. By Method
  • 9.2.4. By Application
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Test Type
      • 9.3.1.2.3. By Method
      • 9.3.1.2.4. By Application
      • 9.3.1.2.5. By End User
  • 9.3.2. UAE Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Test Type
      • 9.3.2.2.3. By Method
      • 9.3.2.2.4. By Application
      • 9.3.2.2.5. By End User
  • 9.3.3. South Africa Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Test Type
      • 9.3.3.2.3. By Method
      • 9.3.3.2.4. By Application
      • 9.3.3.2.5. By End User

10. South America Non-invasive Prenatal Testing (NIPT) Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Test Type
  • 10.2.3. By Method
  • 10.2.4. By Application
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Test Type
      • 10.3.1.2.3. By Method
      • 10.3.1.2.4. By Application
      • 10.3.1.2.5. By End User
  • 10.3.2. Colombia Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Test Type
      • 10.3.2.2.3. By Method
      • 10.3.2.2.4. By Application
      • 10.3.2.2.5. By End User
  • 10.3.3. Argentina Non-invasive Prenatal Testing (NIPT) Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Test Type
      • 10.3.3.2.3. By Method
      • 10.3.3.2.4. By Application
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Non-invasive Prenatal Testing (NIPT) Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. YOURGENE HEALTH Plc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Illumina, Inc.
• 15.3. Natera, Inc.
• 15.4. F.Hoffman La Roche Ltd.
• 15.5. Perkin Elmer Inc.
• 15.6. Laboratory Corporation of America Holdings
• 15.7. Eurofins LifeCodex GmbH
• 15.8. Progenity, Inc.
• 15.9. Genesis Genetics
• 15.10. Quest Diagnostics Incorporated

16. Strategic Recommendations

17. About Us & Disclaimer